Floatz logo

Oxodotreotide

Neuroectodermal Tumors

Sociedad Española de Medicina Nuclear e Imagen Molecularprotein_peptideActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Neuroectodermal Tumors cohort.

Asset / SponsorPhaseRating
Pembrolizumab
DNAtrix, Inc.
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
TASADENOTUREV
DNAtrix, Inc.
Phase 2B
Belzutifan
José Claudio Casali da Rocha
Phase 2CCC
axp107-11
University of Virginia
Phase 2CCC

View all 21 →

Same molecule, other indications

Oxodotreotide is also rated in:

pancreatic neuroendocrine tumorDormant
BBB
Indicative ·
75 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Dormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →